Oxidative stress and AICD in memory T cell persistence
记忆 T 细胞持久性中的氧化应激和 AICD
基本信息
- 批准号:8658396
- 负责人:
- 金额:$ 28.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-06-02 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdoptive ImmunotherapyAffectAffinityAntigensAntioxidantsApoptosisBeliefBiologicalCD4 Positive T LymphocytesCD8B1 geneCancer PatientCell DeathCell surfaceCellsCessation of lifeChronicDataDevelopmentEnzymesEpitopesEvaluationFailureGenerationsGoalsHLA-A2 AntigenHomingHumanHydrogen PeroxideImmuneImmune responseImmune systemImmunityImmunotherapyIn VitroLeadLinkLymphocyteMalignant - descriptorMalignant NeoplasmsMediatingMemoryMolecularMonophenol MonooxygenaseMusNamesOutcomeOxidation-ReductionOxidative StressPathway interactionsPatientsPeptidesPhenotypePhysiologicalPlayPopulationPre-Clinical ModelPredispositionProcessProductionProtocols documentationReactive Nitrogen SpeciesReactive Oxygen SpeciesRegulatory T-LymphocyteResearchResistanceRoleSignal PathwaySignaling MoleculeSulfhydryl CompoundsSuperoxide DismutaseSuperoxidesT cell responseT cell therapyT memory cellT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsTransgenic MiceTransgenic OrganismsTumor-Infiltrating LymphocytesTyrosineVaccinationViralWorkbasecancer immunotherapycytokineexperiencegranulocyteimprovedin vivoin vivo Modelinhibitor/antagonistlong term memorymacrophagemimeticsneoplastic cellnovelprematurepublic health relevanceresponsetranscription factortumortumor growth
项目摘要
DESCRIPTION (provided by applicant): CD8+ T cells respond to antigen stimulation through a process of activation, division, and differentiation to generate a large pool of activated effector cytolytic T lymphocytes (CTL). Many cancer patients harbor precursor CTL that can be activated to respond to many "self" tumor-associated epitopes. Vaccination with some of these epitopes can induce anti-tumor responses in some cases. However, various molecular and cellular mechanisms that tumors develop to successfully evade the host immune system have been identified. Some of these mechanisms target anti-tumor effector CTL that cannot be corrected by immunotherapy aimed only at activation of anti-tumor immune responses. Our preliminary data shows that effector memory phenotype bearing T cell becomes preferentially dysfunctional under conditions of exogenous oxidative stress but also undergo increased activation induced cell death (AICD) on antigenic encounter. Increased superoxide production can be seen in CTL undergoing AICD that can be rescued by pretreatment with superoxide dismutase mimetic MnTBAP. Based on our preliminary data we hypothesize that differential redox status between memory T cell subsets regulates the sensitivity towards AICD or apoptosis. Using MART-127-35 epitope specific human CTL and T cells from our novel transgenic h3T mouse that carries HLA-A2 restricted tyrosine specific functional TCR on both CD4+ and CD8+ T cells we propose to carry out the following: 1) To determine if differential redox state of the T cell subsets (TCM vs. TEM) regulates sensitivity to oxidative stress induced apoptosis and AICD by effecting intrinsic signaling molecules.; 2) To determine extrinsic factors that differentially regulate oxidative stress mediated apoptosis and AICD of memory T cell subsets (TCM vs. TEM); and 3) To establish an in vivo model for evaluation of antioxidant treated T cells or antioxidant enzyme transduced T cells in tumor regression, persistence and memory. We believe that successful completion of the proposed work would help identify targets that could be used to improve survival of effector CTL and long-term memory development in patients receiving adoptive T cell therapy for cancer.
描述(申请人提供):CD8+T细胞通过活化、分裂和分化过程对抗原刺激作出反应,以产生大量激活的效应性溶细胞T淋巴细胞(CTL)。许多癌症患者体内有前体CTL,可被激活以对许多“自身”肿瘤相关表位作出反应。在某些情况下,接种这些表位中的一些可以诱导抗肿瘤反应。然而,肿瘤发展为成功逃避宿主免疫系统的各种分子和细胞机制已经被识别。其中一些机制针对的是抗肿瘤效应器CTL,而免疫疗法仅针对激活抗肿瘤免疫反应而不能纠正这些CTL。我们的初步数据显示,在外源性氧化应激条件下,携带T细胞的效应记忆表型优先发生功能障碍,但在抗原遭遇时也会经历更多的激活诱导细胞死亡(AICD)。在接受AICD的CTL中,可以看到超氧化物歧化产物的增加,这可以通过超氧化物歧化酶模拟物MnTBAP的预处理来挽救。根据我们的初步数据,我们假设记忆T细胞亚群之间不同的氧化还原状态调节着对AICD或细胞凋亡的敏感性。利用MART-127-35表位特异的人CTL和来自我们的新型转基因H3T小鼠的T细胞,并在CD4+和CD8+T细胞上同时携带HLA-A2限制性酪氨酸特异功能TCR,我们建议进行以下研究:1)确定T细胞亚群的不同氧化还原状态是否通过影响内在信号分子而调节对氧化应激诱导的细胞凋亡和AICD的敏感性;2)确定不同调控氧化应激介导的细胞凋亡和记忆T细胞亚群的AICD的外在因素;3)建立体内模型,以评价抗氧化剂处理的T细胞或抗氧化酶转导的T细胞在肿瘤消退、持久性和记忆性方面的作用。我们相信,这项拟议工作的成功完成将有助于确定可用于改善接受癌症采用T细胞疗法的患者的效应型CTL存活和长期记忆发展的靶点。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Dietary agents in cancer prevention: an immunological perspective.
- DOI:10.1111/j.1751-1097.2012.01128.x
- 发表时间:2012-09
- 期刊:
- 影响因子:3.3
- 作者:Zheng YY;Viswanathan B;Kesarwani P;Mehrotra S
- 通讯作者:Mehrotra S
Apoptosis - an Ubiquitous T cell Immunomodulator.
- DOI:10.4172/2155-9899.s3-002
- 发表时间:2011-12-10
- 期刊:
- 影响因子:0
- 作者:Murali AK;Mehrotra S
- 通讯作者:Mehrotra S
Dynamic Metabolism in Immune Response.
免疫反应中的动态代谢。
- DOI:
- 发表时间:2016
- 期刊:
- 影响因子:0
- 作者:Al-Hommrani,Mazen;Chakraborty,Paramita;Chatterjee,Shilpak;Mehrotra,Shikhar
- 通讯作者:Mehrotra,Shikhar
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shikhar Mehrotra其他文献
Shikhar Mehrotra的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shikhar Mehrotra', 18)}}的其他基金
Increasing Thiols for Improving T cell Immunotherapy
增加硫醇以改善 T 细胞免疫治疗
- 批准号:
10603006 - 财政年份:2022
- 资助金额:
$ 28.8万 - 项目类别:
Intersections of RNA-binding proteins and T-cells in oral epithelial plasticity
RNA结合蛋白和T细胞在口腔上皮可塑性中的交叉点
- 批准号:
10417171 - 财政年份:2020
- 资助金额:
$ 28.8万 - 项目类别:
Understanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cells
了解强效抗肿瘤 T 细胞中的代谢和表观遗传交叉对话
- 批准号:
10400117 - 财政年份:2020
- 资助金额:
$ 28.8万 - 项目类别:
Intersections of RNA-binding proteins and T-cells in oral epithelial plasticity
RNA结合蛋白和T细胞在口腔上皮可塑性中的交叉点
- 批准号:
10178000 - 财政年份:2020
- 资助金额:
$ 28.8万 - 项目类别:
Programming Metabolically Fit TILs for Immunotherapy
为免疫疗法编程适合代谢的 TIL
- 批准号:
9906726 - 财政年份:2020
- 资助金额:
$ 28.8万 - 项目类别:
Understanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cells
了解强效抗肿瘤 T 细胞中的代谢和表观遗传交叉对话
- 批准号:
10599308 - 财政年份:2020
- 资助金额:
$ 28.8万 - 项目类别:
Understanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cells
了解强效抗肿瘤 T 细胞中的代谢和表观遗传交叉对话
- 批准号:
10163144 - 财政年份:2020
- 资助金额:
$ 28.8万 - 项目类别:
Intersections of RNA-binding proteins and T-cells in oral epithelial plasticity
RNA结合蛋白和T细胞在口腔上皮可塑性中的交叉点
- 批准号:
10632129 - 财政年份:2020
- 资助金额:
$ 28.8万 - 项目类别:
Programming Metabolically Fit TILs for Immunotherapy
为免疫疗法编程适合代谢的 TIL
- 批准号:
10822377 - 财政年份:2020
- 资助金额:
$ 28.8万 - 项目类别:
Anti-oxidant and Metabolic Phenotype in Regulating Tumor Specific T cell Memory Response
抗氧化和代谢表型调节肿瘤特异性 T 细胞记忆反应
- 批准号:
10300448 - 财政年份:2019
- 资助金额:
$ 28.8万 - 项目类别:
相似海外基金
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
VLA-4™ 靶向 67Cu-LLP2A 预处理增强基于 T 细胞的过继免疫疗法的疗效
- 批准号:
10713034 - 财政年份:2023
- 资助金额:
$ 28.8万 - 项目类别:
Phase I first-in-human trial for ThINKK adoptive immunotherapy in children with high-risk cancers
针对高危癌症儿童的ThINKK过继免疫疗法的I期首次人体试验
- 批准号:
484371 - 财政年份:2023
- 资助金额:
$ 28.8万 - 项目类别:
Operating Grants
Phase I first-in-human trial of ThINKK adoptive immunotherapy in children with high-risk cancers
针对高危癌症儿童的ThINKK过继免疫疗法的I期首次人体试验
- 批准号:
473376 - 财政年份:2022
- 资助金额:
$ 28.8万 - 项目类别:
Operating Grants
Development of Adoptive Immunotherapy Focusing on Follicular Helper T Cell Biology
专注于滤泡辅助 T 细胞生物学的过继免疫疗法的发展
- 批准号:
21K16420 - 财政年份:2021
- 资助金额:
$ 28.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10180117 - 财政年份:2021
- 资助金额:
$ 28.8万 - 项目类别:
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10364687 - 财政年份:2021
- 资助金额:
$ 28.8万 - 项目类别:
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10599851 - 财政年份:2021
- 资助金额:
$ 28.8万 - 项目类别:
Development of a combinatorial approach of antibody therapeutics and adoptive immunotherapy for cancer
开发抗体疗法和癌症过继免疫疗法的组合方法
- 批准号:
21K19422 - 财政年份:2021
- 资助金额:
$ 28.8万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Elucidation of the function of the new NK cell subset and its application to adoptive immunotherapy
阐明新NK细胞亚群的功能及其在过继性免疫治疗中的应用
- 批准号:
21H04832 - 财政年份:2021
- 资助金额:
$ 28.8万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Adoptive immunotherapy for adult T-cell leukemia/lymphoma with ex vivo expanded multi-tumor associated antigen specific cytotoxic T-cells
使用离体扩增的多肿瘤相关抗原特异性细胞毒性 T 细胞对成人 T 细胞白血病/淋巴瘤进行过继免疫治疗
- 批准号:
20K17375 - 财政年份:2020
- 资助金额:
$ 28.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists